Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
US-2017210731-A1 · Jul 27, 2017 · US
Antiproliferative compounds and methods of use thereof
US10357489B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10357489-B2 |
| Application number | US-201816030695-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 9, 2018 |
| Priority date | Jul 10, 2017 |
| Publication date | Jul 23, 2019 |
| Grant date | Jul 23, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, wherein the compound is Compound 1of formula or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. 2. A compound, wherein the compound is Compound 2 of formula or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is Compound 1 of formula 4. The compound of claim 1 , wherein the compound is an enantiomer of Compound 1. 5. The compound of claim 1 , wherein the compound is a mixture of enantiomers of Compound 1. 6. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of Compound 1. 7. The compound of claim 2 , wherein the compound is Compound 2 of formula 8. The compound of claim 2 , wherein the compound is a pharmaceutically acceptable salt of Compound 2. 9. A pharmaceutical composition, comprising the compound of claim 1 . 10. A pharmaceutical composition, comprising the compound of claim 2 . 11. A method of treating multiple myeloma comprising administering a therapeutically effective amount of the compound of claim 1 to a patient in need thereof. 12. The method of claim 11 , wherein the multiple myeloma is relapsed, refractory or resistant. 13. The method of claim 12 , wherein the multiple myeloma is refractory or resistant to lenalidomide. 14. The method of claim 12 , wherein the multiple myeloma is refractory or resistant to pomalidomide. 15. The method of claim 11 , wherein the multiple myeloma is newly diagnosed multiple myeloma. 16. The method of claim 11 , additionally comprising administering a second active agent. 17. The method of claim 16 , wherein the second active agent is dexamethasone. 18. The method of claim 16 , wherein the second active agent is bortezomib. 19. A method of treating multiple myeloma comprising administering a therapeutically effective amount of the compound of claim 2 to a patient in need thereof. 20. The method of claim 19 , wherein the multiple myeloma is relapsed, refractory or resistant. 21. The method of claim 20 , wherein the multiple myeloma is refractory or resistant to lenalidomide. 22. The method of claim 20 , wherein the multiple myeloma is refractory or resistant to pomalidomide. 23. The method of claim 19 , wherein the multiple myeloma is newly diagnosed multiple myeloma. 24. The method of claim 19 , additionally comprising administering a second active agent. 25. The method of claim 24 , wherein the second active agent is dexamethasone. 26. The method of claim 24 , wherein the second active agent is bortezomib.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title
- C07D401/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10357489B2 cover?
- Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds,…
- Who is the assignee on this patent?
- Celgene Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).